Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Coronary Artery Disease Interventions
share announcement

Coronary Artery Disease Interventions

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (5 October 2023) | Viewed by 23440

Special Issue Editors

Dr. Toth-Gayor Gabor

E-Mail Website
Guest Editor
Med Univ Graz, Univ Heart Ctr Graz, Dept Cardiol, Graz, Austria
Interests: coronary artery disease
Dr. Dirk Von Lewinski

E-Mail Website
Guest Editor
Medizinische Universität Grazdisabled, 8036 Graz, Auenbruggerplatz 15, Austria
Interests: coronary artery disease

Special Issue Information

Dear Colleagues,

The treatment of patients with severe ischemic heart disease, regardless of being acute or chronic, is one of the greatest challenges in cardiology. Accordingly, we dedicate this Special Issue to this patient subgroup, including the interventional aspects (i.e., complex, high-risk, indicated procedures (CHIP)), intensive medicine and shock-related topics, as well as pharmacologic aspects.

This Special Issue (SI) of the Journal of Clinical Medicine, entitled “JCM—Coronary artery disease/cardiovascular interventions”, focuses on recent advances in the interventional as well as pharmacological therapy of severely ill or high-risk patients. It aims to reflect the interaction and collaboration of interventional cardiology and intensive care medicine and will publish ground-breaking research articles of significant clinical and scientific value, including observational studies, review articles and clinical trials. Unique clinical cases, particularly supported by cutting-edge imaging or advanced mechanical support, will also be welcome.

Dr. Toth-Gayor Gabor
Dr. Dirk Von Lewinski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (12 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 167 KiB  
Editorial
Special Issue “Coronary Artery Disease Interventions”
by Lukas Herold, Gabor G. Toth and Dirk von Lewinski
J. Clin. Med. 2024, 13(3), 817; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm13030817 - 31 Jan 2024
Viewed by 527
Abstract
The treatment and burden of patients with severe ischemic heart disease, whether acute or chronic, remain some of the greatest challenges in cardiology [...] Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)

Research

Jump to: Editorial, Review

9 pages, 236 KiB  
Article
Outcomes of ECLS-SHOCK Eligibility Criteria Applied to a Real-World Cohort
by Dirk von Lewinski, Lukas Herold, Eva Bachl, Heiko Bugger, Theresa Glantschnig, Ewald Kolesnik, Nicolas Verheyen, Martin Benedikt, Markus Wallner, Friederike von Lewinski, Albrecht Schmidt, Stefan Harb, Klemens Ablasser, Michael Sacherer, Daniel Scherr, Martin Manninger-Wünscher, Sascha Pätzold, Johannes Gollmer, Andreas Zirlik and Gabor G. Toth
J. Clin. Med. 2023, 12(22), 6988; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12226988 - 08 Nov 2023
Cited by 2 | Viewed by 862
Abstract
Background: Cardiogenic shock (CS) exhibits high (~50%) in-hospital mortality. The recently published Extracorporeal life Support in Cardiogenic Shock (ECLS-SHOCK) trial demonstrated the neutral effects of the use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) on all-cause death, as well as on all secondary outcomes [...] Read more.
Background: Cardiogenic shock (CS) exhibits high (~50%) in-hospital mortality. The recently published Extracorporeal life Support in Cardiogenic Shock (ECLS-SHOCK) trial demonstrated the neutral effects of the use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) on all-cause death, as well as on all secondary outcomes in subjects presenting with myocardial-infarction (MI)-related CS. Here, we compared ECLS-SHOCK eligibility criteria with a real-world cohort of CS patients. Methods and Results: ECLS-SHOCK eligibility criteria were applied to a prospective single-center CS registry (the PREPARE CS registry) consisting of 557 patients who were consecutively admitted to the catheterization laboratory (cath lab) of the Medical University of Graz, Austria, due to CS (SCAI C-E). Overall use of mechanical circulatory support (MCS) in this cohort was 19%. Sixty-nine percent of the entire cohort had MI-related CS, 38% of whom would have met ECLS-SHOCK eligibility criteria, thus representing only 27% of the PREPARE CS registry. Exclusion from the ECLS-SHOCK trial was based on patients with initial lactate values below 3 mmol/L (n = 168; 43.6%), aged over 80 years (n = 65; 16.9%), and with a duration of cardiopulmonary resuscitation (CPR) exceeding 45 min (n = 22; 5.7%). The 30-day mortality of patients of the PREPARE CS registry who met the ECLS-SHOCK eligibility criteria was 57.0%, compared to 48.4% of patients in the ECLS-SHOCK trial. The patients’ baseline characteristics, however, differed considerably with respect to type of infarction, age, and gender. Conclusions: In a real-world cohort of patients with MI-related CS, only 38% of patients met the eligibility criteria of the ECLS-SHOCK trial. Thus, the impact of the use of VA-ECMO on outcome parameters in MI-related CS, as observed in the ECLS-SHOCK trial, may differ in a more heterogeneous real-world CS population of the PREPARE CS registry. Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)
11 pages, 445 KiB  
Article
TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement: The TIRATROP Study, A Randomized Controlled Trial
by Thibault Lhermusier, Pascal Motreff, Vincent Bataille, Guillaume Cayla, Bruno Farah, Jerome Roncalli, Meyer Elbaz, Nicolas Boudou, Fransisco Campello-Parada, Frederic Bouisset, Geraud Souteyrand, Emilie Berard, Vanina Bongard and Didier Carrie
J. Clin. Med. 2023, 12(4), 1445; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12041445 - 11 Feb 2023
Cited by 4 | Viewed by 1354
Abstract
Background: Because rotational atherectomy (RA) is associated with arterial trauma and platelet activation, patients treated with RA may benefit from more potent antiplatelet drugs. The aim of this trial was to assess the superiority of ticagrelor over clopidogrel in reducing post procedure troponin [...] Read more.
Background: Because rotational atherectomy (RA) is associated with arterial trauma and platelet activation, patients treated with RA may benefit from more potent antiplatelet drugs. The aim of this trial was to assess the superiority of ticagrelor over clopidogrel in reducing post procedure troponin release. Methods: TIRATROP (TIcagrelor in Rotational Atherectomy to reduce TROPonin enhancement) is a multicenter double-blind randomized controlled trial that included 180 patients with severe calcified lesions requiring RA who received either clopidogrel (300 mg loading dose, then 75 mg/d) or ticagrelor (loading dose 180 mg then 90 mg twice daily). Blood samples were collected at the beginning (T0), and 6, 12, 18, 24 and 36 h after the procedure. Primary end point was troponin release within the first 24 h using area under the curve analysis (troponin level as a function of time). Results: The mean age of patients was 76 ± 10 years, 35% had diabetes. RA was used to treat 1, 2 or 3 calcified lesions in 72%, 23% and 5% of patients, respectively. Troponin release within the first 24 h was similar in both the ticagrelor (adjusted mean ±SD of ln AUC 8.85 ± 0.33) and the clopidogrel (8.77 ± 0.34, p = 0.60) arms. Independent predictors for troponin enhancement were acute coronary syndrome presentation, renal failure, elevated C-Reactive protein and multiple lesions treated with RA. Conclusion: Troponin release did not differ among treatment arms. Our results suggest that greater platelet inhibition does not affect periprocedural myocardial necrosis in the setting of RA. Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)
►▼ Show Figures

Figure 1

10 pages, 1035 KiB  
Article
Distal Radial Artery Access for Recanalization of Radial Artery Occlusion and Repeat Intervention: A Single Center Experience
by Alexandru Achim, Kornél Kákonyi, Zoltán Jambrik, Dorottya Olajos, Attila Nemes, Olivier F. Bertrand and Zoltán Ruzsa
J. Clin. Med. 2022, 11(23), 6916; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11236916 - 23 Nov 2022
Cited by 6 | Viewed by 1899
Abstract
Background: Once occluded, the radial artery becomes unsuitable for repeat interventions and obligates the need for alternative vascular access, such as the femoral approach, which is not encouraged by current guidelines. With the dissemination of distal radial access (DRA), which allows the [...] Read more.
Background: Once occluded, the radial artery becomes unsuitable for repeat interventions and obligates the need for alternative vascular access, such as the femoral approach, which is not encouraged by current guidelines. With the dissemination of distal radial access (DRA), which allows the cannulation of the artery in its distal segment and which remains patent even in the case of radial artery occlusion (RAO), the option to perform angioplasty at this level becomes feasible. Methods: Thirty patients with RAO were enrolled in this pilot study. Recanalization was performed through DRA using hydrophilic guidewires. The feasibility endpoint was procedural success, namely the successful RAO recanalization, the efficacy endpoint was patency of the artery at 30 days, and the safety endpoint was the absence of periprocedural vascular major complications or major adverse cardiac and cerebrovascular events. Results: The mean age of the patients was 63 ± 11 years, and 15 patients (50%) were men. Most patients had asymptomatic RAO (n = 28, 93.3%), and only two (6.6%) reported numbness in their hands. The most common indication for the procedure was PCI (19, 63.2%). Total procedural time was 41 ± 22 min, while the amount of contrast used was 140 ± 28 mL. Procedural success was 100% (n = 30). Moreover, there were no major vascular complications (0%); only two small hematomas were described (10%) and one had an angiographically visible perforation (3%). One case of periprocedural stroke was reported (3%), with onset immediately after the procedure and recovering 24 h later. Twenty-seven radial arteries (90%) remained patent at the one-month follow-up. Conclusions: RAO recanalization is feasible and safe, and by using dedicated hydrophilic guidewires, the success rate is high without significantly increasing procedural time or the amount of used contrast. Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)
►▼ Show Figures

Figure 1

16 pages, 1714 KiB  
Article
Long-Term Survival and Quality of Life in Non-Surgical Adult Patients Supported with Veno-Arterial Extracorporeal Oxygenation
by Tomaž Cankar, Mihela Krepek, Marinos Kosmopoulos, Peter Radšel, Demetris Yannopoulos, Marko Noc and Tomaž Goslar
J. Clin. Med. 2022, 11(21), 6452; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11216452 - 31 Oct 2022
Cited by 3 | Viewed by 1257
Abstract
Background: The use of veno-arterial extracorporeal membrane oxygenation (VA ECMO) for hemodynamic support is on the rise. Not much is known about the impact of extracorporeal membrane oxygenation (ECMO) and its complications on long-term survival and quality of life. Methods: In this single-center, [...] Read more.
Background: The use of veno-arterial extracorporeal membrane oxygenation (VA ECMO) for hemodynamic support is on the rise. Not much is known about the impact of extracorporeal membrane oxygenation (ECMO) and its complications on long-term survival and quality of life. Methods: In this single-center, cross-sectional study, we evaluated the survival and quality of life in patients treated with VA ECMO between May 2009 and July 2019. Follow-up was conducted between November 2019 and January 2020. Results: Overall, 118 patients were evaluated in this study. Of the 37 patients who were alive at hospital discharge, 32 answered the EuroQol-5 dimensional—5-level questionnaire (EQ-5D-5L). For patients discharged alive from the hospital, mean survival was 8.1 years, 8.4 years for cardiogenic shock, and 5.0 years for patients with refractory cardiac arrest. EQ-5D-5L index value of ECMO survivors was not significantly different from the general age-matched population. Neurologic complications and major bleeding during index hospitalization limit long-term quality of life. Conclusions: Patients treated with VA ECMO have high in-hospital mortality, with extracorporeal membrane oxygenation cardio-pulmonary resuscitation patients being at higher risk of early death. However, once discharged from the hospital, most patients remain alive with a reasonable quality of life. Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)
►▼ Show Figures

Figure 1

12 pages, 626 KiB  
Article
Effect of Stenting Strategy on the Outcome in Patients with Non-Left Main Bifurcation Lesions
by Yongwhan Lim, Min Chul Kim, Youngkeun Ahn, Doo Sun Sim, Young Joon Hong, Ju Han Kim, Myung Ho Jeong, Hyeon-Cheol Gwon, Hyo-Soo Kim, Seung Woon Rha, Jung Han Yoon, Yangsoo Jang, Seung-Jea Tahk and Ki Bae Seung
J. Clin. Med. 2022, 11(19), 5658; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11195658 - 26 Sep 2022
Cited by 1 | Viewed by 1206
Abstract
Previous studies have not compared outcomes between different percutaneous coronary intervention (PCI) strategies and lesion locations in non-left main (LM) bifurcation lesions. We enrolled 2044 patients from a multicenter registry with an LAD bifurcation lesion (n = 1551) or non-LAD bifurcation lesion (n [...] Read more.
Previous studies have not compared outcomes between different percutaneous coronary intervention (PCI) strategies and lesion locations in non-left main (LM) bifurcation lesions. We enrolled 2044 patients from a multicenter registry with an LAD bifurcation lesion (n = 1551) or non-LAD bifurcation lesion (n = 493). The primary outcome was target lesion failure (TLF), a composite of cardiac death, myocardial infarction, and target lesion revascularization (TLR). During a median follow-up period of 38 months, non-LAD bifurcation lesions treated with the two-stent strategy, compared with the one-stent strategy, were associated with more frequent TLF (20.7% vs. 6.3%, p < 0.01), TLR (16.7% vs. 4.7%, p < 0.01), and target vessel revascularization (TVR; 18.2% vs. 6.3%, p < 0.01). There was no significant difference in outcome among LAD bifurcation lesions treated with different PCI strategies. The two-stent strategy was associated with a higher risk of TLF (adjusted HR 4.34, CI 1.93–9.76, p < 0.01), TLR (adjusted HR 4.30, CI 1.64–11.27, p < 0.01), and TVR (adjusted HR 5.07, CI 1.69–9.74, p < 0.01) in the non-LAD bifurcation lesions. The planned one-stent strategy is preferable to the two-stent strategy for the treatment of non-LAD bifurcation lesions. Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)
►▼ Show Figures

Figure 1

17 pages, 1977 KiB  
Article
Independent Clinical Impacts of Procedural Complexity on Ischemic and Bleeding Events in Patients with Acute Myocardial Infarction: Long-Term Clinical Study
by Kwan Yong Lee, Byung-Hee Hwang, Sungmin Lim, Chan Jun Kim, Eun-Ho Choo, Seung Hoon Lee, Jin-Jin Kim, Ik Jun Choi, Gyu Chul Oh, In-Ho Yang, Ki Dong Yoo, Wook Sung Chung, Youngkeun Ahn, Myung Ho Jeong and Kiyuk Chang
J. Clin. Med. 2022, 11(16), 4853; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11164853 - 18 Aug 2022
Cited by 1 | Viewed by 1581
Abstract
This study aimed to investigate the relationship between a complex percutaneous coronary intervention (C-PCI) and long-term clinical outcomes in the AMI cohort. A total of 10,329 patients were categorized into the C-PCI and non-C-PCI groups. The primary ischemic endpoint was a composite of [...] Read more.
This study aimed to investigate the relationship between a complex percutaneous coronary intervention (C-PCI) and long-term clinical outcomes in the AMI cohort. A total of 10,329 patients were categorized into the C-PCI and non-C-PCI groups. The primary ischemic endpoint was a composite of major adverse cardiac events (MACEs, cardiac death, myocardial infarction, stent thrombosis and revascularization). The primary bleeding endpoint was the risk of overt bleeding (BARC 2, 3 or 5). The median follow-up duration was 4.9 (2.97, 7.16) years. The risks of MACEs and bleeding were significantly higher in the C-PCI group (hazard ratio (HR): 1.72; 95% confidence interval (CI): 1.60 to 1.85; p < 0.001; and HR: 1.32; 95% CI: 1.17 to 1.50; p < 0.001, respectively). After propensity score matching, compared to the non-C-PCI group, the adjusted MACE rate in C-PCI remained significantly higher (p < 0.001), but no significant interaction (p = 0.273) was observed for bleeding. Significant differences in overt bleeding were observed only within the first three months (p = 0.024). The MACEs were consistently higher in the C-PCI group with or without severe comorbid conditions (p < 0.001 for both). Patients with AMI who undergo C-PCI experience worse long-term ischemic outcomes after successful PCI, regardless of the presence of severe comorbidities. Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)
►▼ Show Figures

Figure 1

13 pages, 1445 KiB  
Article
Clinical Outcomes of Different Calcified Culprit Plaques in Patients with Acute Coronary Syndrome
by Fangmeng Lei, Yanwei Yin, Xiaohui Liu, Chao Fang, Senqing Jiang, Xueming Xu, Sibo Sun, Xueying Pei, Ruyi Jia, Caiying Tang, Cong Peng, Song Li, Lulu Li, Yini Wang, Huai Yu, Jiannan Dai and Bo Yu
J. Clin. Med. 2022, 11(14), 4018; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11144018 - 11 Jul 2022
Cited by 3 | Viewed by 1671
Abstract
Background: Previous studies have found that coronary artery calcification is closely associated with the occurrence of major adverse cardiac events (MACE). This study aimed to investigate the characteristics and clinical outcomes of different calcified plaques in patients with acute coronary syndrome (ACS) by [...] Read more.
Background: Previous studies have found that coronary artery calcification is closely associated with the occurrence of major adverse cardiac events (MACE). This study aimed to investigate the characteristics and clinical outcomes of different calcified plaques in patients with acute coronary syndrome (ACS) by using optical coherence tomography (OCT). Methods: 258 ACS patients with calcified culprit plaques who underwent OCT-guided stent implantation were enrolled. They were divided into three subtypes based on the calcified plaque morphology, including eruptive calcified nodules, calcified protrusion, and superficial calcific sheet. Results: Compared with superficial calcific sheet and calcified protrusion, eruptive calcified nodules had the greatest calcium burden and a higher rate of stent edge dissection (p < 0.001) and incomplete stent apposition (p < 0.001). In a median follow-up period of 2 years, 39 (15.1%) patients experienced MACE (a composite event of cardiac death, target-vessel myocardial infarction, ischemia-driven revascularization), with a significantly higher incidence in the eruptive calcified nodules group (32.1% vs. 10.1% vs. 13.0%, p = 0.001). A multivariate Cox analysis demonstrated that the eruptive calcified nodules (hazard ratio 3.14; 95% confidence interval, 1.64–6.02; p = 0.001) were an independent predictor of MACE. Conclusions: MACE occurred more frequently in ACS patients with eruptive calcified nodules, and the eruptive calcified nodules were an independent predictor of MACE. Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)
►▼ Show Figures

Figure 1

12 pages, 992 KiB  
Article
Long-Term Performance of the Magmaris Drug-Eluting Bioresorbable Metallic Scaffold in All-Comers Patients’ Population
by Arif Al Nooryani, Wael Aboushokka, Bassam AlBaba, Jalal Kerfes, Loai Abudaqa, Amit Bhatia, Anoop Mansoor, Ruwaide Nageeb, Srdjan Aleksandric and Branko Beleslin
J. Clin. Med. 2022, 11(13), 3726; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11133726 - 28 Jun 2022
Cited by 3 | Viewed by 1494
Abstract
Background: The long-term efficacy and safety of bioresorbable vascular scaffolds (BVS) in real world clinical practice including Magmaris need to be elucidated to better understand performance of this new and evolutive technology. The aim of this study was to evaluate long-term performance [...] Read more.
Background: The long-term efficacy and safety of bioresorbable vascular scaffolds (BVS) in real world clinical practice including Magmaris need to be elucidated to better understand performance of this new and evolutive technology. The aim of this study was to evaluate long-term performance of Magmaris, drug-eluting bioresorbable metallic scaffold, in all-comers patients’ population. Methods: We included in this prospective registry first 54 patients (54 ± 11 years; male 46) treated with Magmaris, with at least 30 months of follow-up. Diabetes mellitus and acute coronary syndrome were present in 33 (61%) and 30 (56%) of the patients, respectively. Patients were followed for device- and patient-oriented cardiac events during a median follow-up of 47 months (DOCE–cardiac death, target vessel myocardial infarction, and target lesion revascularization; POCE–all cause death, any myocardial infarction, any revascularization). Results: Event-free survivals for DOCE and POCE were 86.8% and 79.2%, respectively. The rate of DOCE was 7/54 (13%), including in total target vessel myocardial infarction in two patients (4%), target lesion revascularization in six patients (11%), and no cardiac deaths. The rate of POCE was 11/54 (21%), including in total any myocardial infarctions in 3 patients (6%), any revascularization in 11 patients (20%), and no deaths. Definite Magmaris thrombosis occurred in two patients (3.7%), and in-scaffold restenosis developed in five patients (9.3%). Variables associated with DOCE were implantation of ≥2 Magmaris BVS (HR: 5.4; 95%CI: 1.21–24.456; p = 0.027) and total length of Magmaris BVS ≥ 40 mm (HR: 6.4; 95%CI: 1.419–28.855; p = 0.016), whereas previous PCI was the only independent predictor of POCE (HR: 7.4; 95%CI: 2.216–24.613; p = 0.001). Conclusions: The results of the long-term clinical outcome following Magmaris implantation in patients with complex clinical and angiographic features were acceptable and promising. Patients with multi-BVS and longer multi-BVS in lesion implantation were associated with worse clinical outcome. Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)
►▼ Show Figures

Figure 1

11 pages, 945 KiB  
Article
Distal Radial Artery Access for Coronary and Peripheral Procedures: A Multicenter Experience
by Alexandru Achim, Kornél Kákonyi, Zoltán Jambrik, Ferenc Nagy, Julia Tóth, Viktor Sasi, Péter Hausinger, Attila Nemes, Albert Varga, Olivier F. Bertrand and Zoltán Ruzsa
J. Clin. Med. 2021, 10(24), 5974; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm10245974 - 20 Dec 2021
Cited by 18 | Viewed by 2185
Abstract
Introduction: Distal radial access (dRA) has recently gained global popularity as an alternative access route for vascular procedures. Among the benefits of dRA are the low risk of entry site bleeding complications, the low rate of radial artery occlusion, and improved patient and [...] Read more.
Introduction: Distal radial access (dRA) has recently gained global popularity as an alternative access route for vascular procedures. Among the benefits of dRA are the low risk of entry site bleeding complications, the low rate of radial artery occlusion, and improved patient and operator comfort. The aim of this large multicenter registry was to demonstrate the feasibility and safety of dRA in a wide variety of routine procedures in the catheterization laboratory, ranging from coronary angiography and percutaneous coronary intervention to peripheral procedures. Methods: The study comprised 1240 patients who underwent coronary angiography, PCI or noncoronary procedures through dRA in two Hungarian centers from January 2019 to April 2021. Baseline patient characteristics, number and duration of arterial punctures, procedural success rate, crossover rate, postoperative compression time, complications, hospitalization duration, and different learning curves were analyzed. Results: The average patient age was 66.4 years, with 66.8% of patients being male. The majority of patients (74.04%) underwent a coronary procedure, whereas 25.96% were involved in noncoronary interventions. dRA was successfully punctured in 97% of all patients, in all cases with ultrasound guidance. Access site crossover was performed in 2.58% of the patients, mainly via the contralateral dRA. After experiencing 150 cases, the dRA success rate plateaued at >96%. Our dedicated dRA step-by step protocol resulted in high open radial artery (RA) rates: distal and proximal RA pulses were palpable in 99.68% of all patients at hospital discharge. The rate of minor vascular complications was low (1.5%). A threshold of 50 cases was sufficient for already skilled radial operators to establish a reliable procedural method of dRA access. Conclusion: The implementation of distal radial artery access in the everyday routine of a catheterization laboratory for coronary and noncoronary interventions is feasible and safe with an acceptable learning curve. Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial, Research

45 pages, 1756 KiB  
Review
Coronary No-Reflow after Primary Percutaneous Coronary Intervention—Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy
by Gjin Ndrepepa and Adnan Kastrati
J. Clin. Med. 2023, 12(17), 5592; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12175592 - 27 Aug 2023
Cited by 4 | Viewed by 5820
Abstract
Coronary no-reflow (CNR) is a frequent phenomenon that develops in patients with ST-segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is highly dynamic, develops gradually (over hours) and persists for days to weeks after reperfusion. Microvascular obstruction (MVO) developing as a consequence [...] Read more.
Coronary no-reflow (CNR) is a frequent phenomenon that develops in patients with ST-segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is highly dynamic, develops gradually (over hours) and persists for days to weeks after reperfusion. Microvascular obstruction (MVO) developing as a consequence of myocardial ischemia, distal embolization and reperfusion-related injury is the main pathophysiological mechanism of CNR. The frequency of CNR or MVO after primary PCI differs widely depending on the sensitivity of the tools used for diagnosis and timing of examination. Coronary angiography is readily available and most convenient to diagnose CNR but it is highly conservative and underestimates the true frequency of CNR. Cardiac magnetic resonance (CMR) imaging is the most sensitive method to diagnose MVO and CNR that provides information on the presence, localization and extent of MVO. CMR imaging detects intramyocardial hemorrhage and accurately estimates the infarct size. MVO and CNR markedly negate the benefits of reperfusion therapy and contribute to poor clinical outcomes including adverse remodeling of left ventricle, worsening or new congestive heart failure and reduced survival. Despite extensive research and the use of therapies that target almost all known pathophysiological mechanisms of CNR, no therapy has been found that prevents or reverses CNR and provides consistent clinical benefit in patients with STEMI undergoing reperfusion. Currently, the prevention or alleviation of MVO and CNR remain unmet goals in the therapy of STEMI that continue to be under intense research. Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)
►▼ Show Figures

Figure 1

18 pages, 1191 KiB  
Review
Coronary Microcirculation: The Next Frontier in the Management of STEMI
by Dejan Milasinovic, Olga Nedeljkovic, Ruzica Maksimovic, Dragana Sobic-Saranovic, Djordje Dukic, Vladimir Zobenica, Dario Jelic, Milorad Zivkovic, Vladimir Dedovic, Sanja Stankovic, Milika Asanin and Vladan Vukcevic
J. Clin. Med. 2023, 12(4), 1602; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm12041602 - 17 Feb 2023
Cited by 2 | Viewed by 2319
Abstract
Although the widespread adoption of timely invasive reperfusion strategies over the last two decades has significantly improved the prognosis of patients with ST-segment elevation myocardial infarction (STEMI), up to half of patients after angiographically successful primary percutaneous coronary intervention (PCI) still have signs [...] Read more.
Although the widespread adoption of timely invasive reperfusion strategies over the last two decades has significantly improved the prognosis of patients with ST-segment elevation myocardial infarction (STEMI), up to half of patients after angiographically successful primary percutaneous coronary intervention (PCI) still have signs of inadequate reperfusion at the level of coronary microcirculation. This phenomenon, termed coronary microvascular dysfunction (CMD), has been associated with impaired prognosis. The aim of the present review is to describe the collected evidence on the occurrence of CMD following primary PCI, means of assessment and its association with the infarct size and clinical outcomes. Therefore, the practical role of invasive assessment of CMD in the catheterization laboratory, at the end of primary PCI, is emphasized, with an overview of available technologies including thermodilution- and Doppler-based methods, as well as recently developing functional coronary angiography. In this regard, we review the conceptual background and the prognostic value of coronary flow reserve (CFR), index of microcirculatory resistance (IMR), hyperemic microvascular resistance (HMR), pressure at zero flow (PzF) and angiography-derived IMR. Finally, the so-far investigated therapeutic strategies targeting coronary microcirculation after STEMI are revisited. Full article
(This article belongs to the Special Issue Coronary Artery Disease Interventions)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-12
Back to TopTop